

S 1909

Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: May 27, 2021

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (May 27, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/1909>

Sponsor

Name: Sen. Tester, Jon [D-MT]

Party: Democratic • **State:** MT • **Chamber:** Senate

Cosponsors (14 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Brown, Sherrod [D-OH]	D · OH		May 27, 2021
Sen. Capito, Shelley Moore [R-WV]	R · WV		May 27, 2021
Sen. Lankford, James [R-OK]	R · OK		May 27, 2021
Sen. Hyde-Smith, Cindy [R-MS]	R · MS		Jun 10, 2021
Sen. Marshall, Roger [R-KS]	R · KS		Jun 10, 2021
Sen. Boozman, John [R-AR]	R · AR		Jun 15, 2021
Sen. Collins, Susan M. [R-ME]	R · ME		Jun 15, 2021
Sen. Cramer, Kevin [R-ND]	R · ND		Jun 17, 2021
Sen. Thune, John [R-SD]	R · SD		Jun 17, 2021
Sen. Wicker, Roger F. [R-MS]	R · MS		Jun 24, 2021
Sen. Manchin, Joe, III [D-WV]	D · WV		Jul 21, 2021
Sen. Inhofe, James M. [R-OK]	R · OK		Sep 21, 2021
Sen. King, Angus S., Jr. [I-ME]	I · ME		Oct 21, 2021
Sen. Ernst, Joni [R-IA]	R · IA		Dec 7, 2021

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	May 27, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 3554	Identical bill	May 26, 2021: Referred to the Subcommittee on Health.

Summary (as of May 27, 2021)

Pharmacy DIR Reform To Reduce Senior Drug Costs Act

This bill establishes certain requirements for prescription drug plans and the prices of covered drugs under the Medicare prescription drug benefit.

Specifically, the bill requires price concessions, payments, and fees that are negotiated with a pharmacy to be included in a drug's negotiated price, excluding incentive payments, and for this price to be provided at the point of sale. Additionally, prescription drug plans must report price concessions or incentive payments that are made after payment for covered drugs at the point of sale, including by contracted intermediaries, to the pharmacy at least annually.

The Centers for Medicare & Medicaid Services must establish standardized pharmacy performance measures with respect to incentive payments and price concessions; such measures must account for all pharmacy types, including specialty pharmacies, and focus on patient health outcomes and other targeted areas.

Actions Timeline

- **May 27, 2021:** Introduced in Senate
- **May 27, 2021:** Read twice and referred to the Committee on Finance.